|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||186.75 - 191.27|
|52 Week Range||129.21 - 218.00|
|Beta (5Y Monthly)||0.26|
|PE Ratio (TTM)||27.55|
|Earnings Date||Apr 27, 2021|
|Forward Dividend & Yield||3.40 (1.78%)|
|Ex-Dividend Date||Feb 11, 2021|
|1y Target Est||215.88|
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) first-quarter sales.
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today results from a second Phase 3 trial (BRAVE-AA1) evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata (AA). The data are consistent with findings from the first Phase 3 clinical trial, BRAVE-AA2, top-lined earlier this year. In both investigational trials, a statistically significant proportion of patients treated with baricitinib achieved the primary endpoint of hair regrowth across the two dosing regimens at Week 36 compared to patients treated with placebo. AA is an autoimmune disease that causes patchy hair loss on the scalp, face and sometimes on other areas of the body that can progress, and currently has no therapies approved by the U.S. Food and Drug Administration (FDA).